Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6605336rdf:typepubmed:Citationlld:pubmed
pubmed-article:6605336lifeskim:mentionsumls-concept:C0038689lld:lifeskim
pubmed-article:6605336lifeskim:mentionsumls-concept:C0039097lld:lifeskim
pubmed-article:6605336lifeskim:mentionsumls-concept:C0041041lld:lifeskim
pubmed-article:6605336lifeskim:mentionsumls-concept:C0205321lld:lifeskim
pubmed-article:6605336pubmed:issue3lld:pubmed
pubmed-article:6605336pubmed:dateCreated1983-12-20lld:pubmed
pubmed-article:6605336pubmed:abstractTextA group of six patients with non-infected synovial effusions requiring diagnostic or therapeutic aspiration, were given a short oral course of 'Septrin' (two tablets bd for two doses, each tablet containing 80 mg of trimethoprim plus 400 mg of sulphamethoxazole). Serum and synovial fluid (SF) were sampled frequently following antibiotic administration. It was found that concentrations of trimethoprim in SF approached serum levels after a short lag time (about 3 h) and thereafter approximated to the serum levels, whereas sulphamethoxazole did not as readily penetrate into SF. With the regimens used MIC levels for trimethoprim were achieved in SF, which suggests that this drug could be usefully prescribed in normal doses for the treatment of septic arthritis due to bacterial infection.lld:pubmed
pubmed-article:6605336pubmed:languageenglld:pubmed
pubmed-article:6605336pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6605336pubmed:citationSubsetIMlld:pubmed
pubmed-article:6605336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6605336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6605336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6605336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6605336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6605336pubmed:statusMEDLINElld:pubmed
pubmed-article:6605336pubmed:monthSeplld:pubmed
pubmed-article:6605336pubmed:issn0305-7453lld:pubmed
pubmed-article:6605336pubmed:authorpubmed-author:KayeC MCMlld:pubmed
pubmed-article:6605336pubmed:authorpubmed-author:HoltJ EJElld:pubmed
pubmed-article:6605336pubmed:authorpubmed-author:CawleyM IMIlld:pubmed
pubmed-article:6605336pubmed:authorpubmed-author:SattarM AMAlld:pubmed
pubmed-article:6605336pubmed:authorpubmed-author:SankeyM GMGlld:pubmed
pubmed-article:6605336pubmed:issnTypePrintlld:pubmed
pubmed-article:6605336pubmed:volume12lld:pubmed
pubmed-article:6605336pubmed:ownerNLMlld:pubmed
pubmed-article:6605336pubmed:authorsCompleteYlld:pubmed
pubmed-article:6605336pubmed:pagination229-33lld:pubmed
pubmed-article:6605336pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:meshHeadingpubmed-meshheading:6605336-...lld:pubmed
pubmed-article:6605336pubmed:year1983lld:pubmed
pubmed-article:6605336pubmed:articleTitleThe penetration of trimethoprim and sulphamethoxazole into synovial fluid.lld:pubmed
pubmed-article:6605336pubmed:publicationTypeJournal Articlelld:pubmed